0001209191-22-035031.txt : 20220608 0001209191-22-035031.hdr.sgml : 20220608 20220608162441 ACCESSION NUMBER: 0001209191-22-035031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220607 FILED AS OF DATE: 20220608 DATE AS OF CHANGE: 20220608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chen Hubert C CENTRAL INDEX KEY: 0001622297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38052 FILM NUMBER: 221003805 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Forte Biosciences, Inc. CENTRAL INDEX KEY: 0001419041 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261243872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1124 W CARSON STREET STREET 2: MRL BUILDING 3-320 CITY: TORRANCE STATE: CA ZIP: 90502 BUSINESS PHONE: (310) 618-6994 MAIL ADDRESS: STREET 1: 1124 W CARSON STREET STREET 2: MRL BUILDING 3-320 CITY: TORRANCE STATE: CA ZIP: 90502 FORMER COMPANY: FORMER CONFORMED NAME: Tocagen Inc DATE OF NAME CHANGE: 20071120 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-07 0 0001419041 Forte Biosciences, Inc. FBRX 0001622297 Chen Hubert C C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6 DALLAS TX 75247 0 1 0 0 See remarks Stock Option (right to buy) 1.30 2022-06-07 4 A 0 250000 0.00 A 2032-06-07 Common Stock 250000 250000 D Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Inducement Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 7, 2022. President and Chief Scientific Officer /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact 2022-06-08